potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)
There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).
FDA is adding a black box warning to these topical immunosuppressants used for eczema. Patients will soon get a Medication Guide when their prescriptions are filled.
It's NOT known for sure if these drugs increase cancer risk.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote